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Background: DNA vaccines offer several advantages over conventional vaccines in the development of effective
vaccines against avian influenza virus (AIV). However, one of the limitations of the DNA vaccine in poultry is that it
induces poor immune responses. In this study, chicken interleukin (IL) -15 and IL-18 were used as genetic adjuvants
to improve the immune responses induced from the H5 DNA vaccination in chickens. The immunogenicity of the
recombinant plasmid DNA was analyzed based on the antibody production, T cell responses and cytokine
production, following inoculation in 1-day-old (Trial 1) and 14-day-old (Trial 2) specific-pathogen-free chickens.
Hence, the purpose of the present study was to explore the role of chicken IL-15 and IL-18 as adjuvants following
the vaccination of chickens with the H5 DNA vaccine.
Results: The overall HI antibody titer in chickens immunized with pDis/H5 + pDis/IL-15 was higher compared to
chickens immunized with pDis/H5 (p < 0.05). The findings revealed that the inoculation of the 14-day-old chickens
exhibited a shorter time to achieve the highest HI titer in comparison to the inoculation of the 1-day-old chickens.
The cellular immunity was assessed by the flow cytometry analysis to enumerate CD4+ and CD8 + T cells in the
peripheral blood. The chickens inoculated with pDis/H5 + pDis/IL-15 demonstrated the highest increase in CD4+
T cells population relative to the control chickens. However, this study revealed that pDis/H5 + pDis/IL-15 was not
significant (P > 0.05) in inducing CD8+ T cells. Meanwhile, with the exception of Trial 1, the flow cytometry results
for Trial 2 demonstrated that the pDis/H5 + pDis/IL-18 inoculated group was able to trigger a higher increase in
CD4+ T cells than the pDis/H5 group (P < 0.05). On the other hand, the pDis/H5 + pDis/IL-18 group was not
significant (P > 0.05) in modulating CD8+ T cells population in both trials. The pDis/H5 + pDis/IL-15 inoculated
group showed the highest IL-15 gene expression in both trials compared to other inoculated groups (P < 0.05).
Similar results were obtained for the IL-18 expression where the pDis/H5 + pDis/IL-18 groups in both trials (Table 8)
were significantly higher compared to the control group (P < 0.05). However, the expressions of other cytokines
remained low or undetected by GeXP assay.
Conclusions: This study shows the diverse immunogenicity of pDis/H5 co-administered with chicken IL-15 and
IL-18,with pDis/H5 + pDis/IL-15 being a better vaccine candidate compared to other groups.
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Avian influenza (AI) is regarded as one of the most
important diseases infecting poultry and other birds
throughout the world. Outbreaks of H5N1, the highly
pathogenic avian influenza (HPAI), in poultry all over
Asia have caused significant economic and public health
difficulties [1]. Traditionally, the control of the HPAI has
been achieved through the culling of infected flocks.
However, the culling of infected poultry flocks alone has
not proven to be sufficient in the eradication of the dis-
ease as the HPAI is endemic to a large geographical area,
with the virus infecting poultry and indigenous wildfowl
[2]. In 2005, in accordance with the recommendations of
the OIE/FAO in collaboration with the WHO, the vac-
cination of uninfected flocks was deemed as one of the
measures to prevent the outbreak and spread of the dis-
ease [2]. In addition, the immunization of poultry can
limit the source of the virus that is responsible for its
transmission to human or mammalian hosts [3]. There-
fore, the development of an efficacious vaccine against
the avian influenza virus (AIV) is desirable.
The main advantages of DNA immunization approaches
include simplicity of delivery, inexpensive rapid mass pro-
duction, and ease of preparation [4] without the safety
concern of incomplete inactivation in the inactivated
whole virus vaccine, which may cause outbreaks [5].
Moreover, DNA vaccines were also able to induce
both humoral and cell-mediated immune responses
[6]. Despite the advantages mentioned, low immuno-
genicity and expression levels, low transfection effi-
ciency and targeting specificity remain the main
obstacles compared to conventional vaccines [6,7].
Thus, the employment of adjuvants might help to
overcome the above obstacles and enhance the
vaccine-induced immune responses.
Genetic adjuvants are expression vectors encoding bio-
logically active molecules such as cytokines, chemokines,
soluble forms of cell ligands, adhesion proteins, or other
immuno-reactive molecules [8]. Although avian cyto-
kines have been poorly defined, they have the potential
to control infectious diseases and can act as vaccine
adjuvants that may specifically activate immune systems
leading to effective protection [9]. It has been shown
that IL-15 in mammals has a major role in natural killerTable 1 List of primers used in amplification and cloning of A
Primer name Primer sequence
H5fSacII 5’ CCC CCG CGG ATG GAG A
H5rAccI 5’ CCC GTC GAC AAT GCA AA
IL-15fSacII 5’ AAA CCG CGG ATG CTG G
IL-15rAccI 5’ GGG GTC GAC CTG GTA AG
IL-18fSacII 5’ CCC CCG CGG ATG AGC TG
IL-18rAccI 5’ CCC GTC GAC AAA GGC Ccell development and proliferation, T cell growth, B cell
proliferation and differentiation, and has an important
influence on the development of CD4+ T cells [10,11].
In addition, IL-15 and IL-18 also play an important role
in the development of T helper 1 cells [12] and were
able to yield stronger CD4+ T cells, CD8+ T cell
responses [13] and induction of NK cells [14]. Hence,
the purpose of the present study was to explore the role
of chicken IL-15 and IL-18 as adjuvants following the
vaccination of chickens with the H5 DNA vaccine.
Methods
Construction of recombinant plasmids DNA
The pDis/H5 plasmid was constructed by sub-cloning
the HA gene of AIV A/Chicken/Malaysia/5744/04
(H5N1) from pCR2.1/H5 into the plasmid expression
vector pDisplay (Invitrogen, USA). The chicken IL-15
[GenBank: AY005476] and IL-18 [GenBank: AJ277865]
clones were obtained from the Delaware Biotechno-
logy Institute, Newark DE, USA. The H5, IL-15 and
IL-18 genes were amplified using forward and reverse
primers with SacII and AccI restriction sites respectively
(Table 1), and ligated to the pDisplay vector. The
selected recombinant clones were further confirmed by
restriction enzyme analysis and sequencing.
Transfection
The Vero cells were seeded in a 6-well plate with a
DMEM medium (Gibco, USA) without antibiotics one
day before the transfection to achieve 90-95% confluence
at the time of transfection. The transfection of the plas-
mid was performed using Lipofectamine (Invitrogen,
USA). A mixture of 3 μg purified plasmid DNA and
6 μL of Lipofectamine (Invitrogen, USA) reagent was
added to the monolayer cells. After a 48-hour post-
transfection period, the cells were trypsinized and sub-
cultured in new flasks with a DMEM medium containing
Geneticin (Invitrogen, USA). The medium was replaced
every 4 days for the next 14 days. The cells were har-
vested and used for further analysis.
Western blotting
The transfected cells were washed with 1X PBS and mixed
with an equal volume of a 2X sample buffer [0.5 M TrisIV genes
Gene size (bp)
AA ATA GTG CTT 3’ H5 gene/1722
T TCT GCA 3’
GG ATG GCA CAG 3’ IL-15 gene/564
T TGC AAA TCT TGC 3’
T GAA GAG ATC 3’ IL-18 gene/486
AA GAA CAT TCC TTG 3’
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mophenol blue, 10% (v/v) β-mercaptoethanol] and short
spun before being heated at 100°C for 10 minutes. The
protein samples were run on 12% SDS-PAGE and there-
after subjected to electro-transfer to a nitrocellulose
membrane with a constant voltage of 15 volts for 90
minutes. The membrane was incubated with a primary
rabbit polyclonal antibody against the avian influenza H5
antibody (Abcam, USA) for 1 hour. The membrane was
washed with washing solution (Invitrogen, USA) and the
process was repeated thrice. The membrane was then
incubated with Rabbit Secondary Antibody Solution
(Invitrogen, USA) for 30 minutes and further washed
thrice. Finally, the blot was incubated with 5 mL of
Chromogenic Substrate solution (BCIP/NBT substrate
for alkaline phosphatase) (Invitrogen, USA) until the
bands appeared.
Indirect immunofluorescence test
The expressed proteins were subjected to the immuno-
fluorescence test using a polyclonal antibody raised in
rabbits and a secondary fluorescein isothiocyanate
(FITC) anti-rabbit antibody raised in goats (KPL, USA).
The stable transfected Vero cells were seeded in a Lab-
Tek™ chamber slide (Nunc, USA) and grown to 70%
confluence. The confluent cells were rinsed with 1X PBS
and overlaid with a primary rabbit polyclonal antibody
against the avian influenza H5 antibody (Abcam, USA)
diluted at 1:1000 and incubated at 37°C for 1 hour. The
chamber slide was washed 3 times with 1X PBS and
FITC anti-rabbit antibody (Abcam, USA) diluted at
1:500, added onto the cells and incubated at 37°C for 1
hour. This was followed by washing the slide 3 times
with PBS and it was then air-dried and mounted in gly-
cerol : 1X PBS (9:1). The mounted slide was then viewed
under an inverted phase contrast microscope with fluor-
escent light (Olympus, USA).
Reverse transcription-polymerase chain reaction
A RT-PCR analysis was performed on the Vero cells to
determine the presence of pDis/H5, pDis/IL-15 and pDis/
IL-18 mRNA transcripts. Briefly, the total RNA was
extracted using Trizol reagent (Invitrogen, USA) and trea-
ted with 2 mL of DNase I (Sigma, UK) at 37°C for 30
minutes and the reaction was stopped with 2 mL of
50 mM EDTA and heat inactivation at 56°C for 10 min-
utes. The extracted RNA was subjected to RT-PCR using
the One Step Access RT-PCR System (Promega, USA).
Amplification was performed in a 25 μL RT-PCR mixture
containing the AMV/Tfl 1X Reaction Buffer, 0.2 mM of
dNTP mixture, 3.0 mM MgSO4, 0.5 μM of each primer
(Vivantis, Malaysia), 0.8 U RNasin Ribonuclease Inhibitor
(Promega, USA), 0.1 U AMV Reverse Transcriptase (Pro-
mega, USA), 0.1 UTfl DNA Polymerase (Promega, USA)and 10 μg of RNA. The reaction mixture was incubated
at 45°C for 45 minutes. The amplification was performed
as follows: initial denaturation at 95°C for 2 minutes fol-
lowed by 30 cycles of denaturation at 95°C for 30 sec-
onds, annealing at 55°C for 44 seconds and extension at
68°C for 2 minutes. Lastly, the mixture was subjected to a
final extension at 68°C for 10 minutes.
Immunization of chickens
The plasmids pDis/H5, pDis/IL-15 and pDis/IL-18 were
extracted and purified using the EndoFree Plasmid Mega
Kit (Qiagen, Germany) according to the manufacturer’s
procedure. In the first trial, five groups of chickens were
established with ten specific-pathogen-free (SPF) chick-
ens per group. The groups were as follows: Group 1,
control group without inoculation; Group 2, control
group inoculated with pDisplay vector; Group 3, vacci-
nated with pDis/H5; Group 4, vaccinated with pDis/
H5 + pDis/IL-15, and Group 5, inoculated with pDis/
H5 + pDis/IL-18. One-day-old chickens were injected
twice with 150 μg of purified plasmid DNAs using
1 mL tuberculin syringes attached with 25 G x 5/8
inch needles with 100 μL of the plasmid DNA solu-
tions through an i.m route on the left pectoral muscle
of the chickens. A booster dose was administered at
2 weeks post inoculation. Bleeding was performed via
the jugular vein and the serum was collected from the
1-day-old chickens at 1, 2, 3, 5, 6 and 7 weeks post in-
oculation. Blood lymphocytes were collected from the
1-day-old chickens at 1 and 5 weeks post inoculation.
The chickens in each group were euthanized at 7 weeks
post inoculation. In the second trial, five groups of
chickens were established with seven SPF chickens per
group. Fourteen-day-old chickens were injected twice
with 150 μg of purified plasmid DNAs as described in
Trial 1. A booster dose was administered at 3 weeks
post inoculation. Bleeding was performed via the jugular
vein and the serum was collected from the 14-day-old
chickens at 3, 4 and 6 weeks post inoculation, whilst
blood lymphocytes were collected from the 14-day-old
chickens at 3 and 6 weeks post inoculation. The chickens
in each group were euthanized at 6 weeks post inocula-
tion. The experimental trials were approved by the
Animal Care and Use Committee at the Faculty of Veter-
inary Medicine, Universiti Putra Malaysia, reference
number, UPM/FPV/PS/3.2.1.551/AUP-R80.
Hemagglutination inhibition (HI) test
The standard HI assay was done on a 96-well V-shape
microtiter plate following the method described by
Vogel and Shelokov [15]. A low pathogenic inactivated
AIV H5N2, A/duck/Malaysia/8443/04 (H5N2) was
obtained from the Veterinary Research Institute, Ipoh.
The virus was titrated at four hemagglutinin activity
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gen for 15 minutes to allow for reaction with the serum,
25 μL of 0.5% (v/v) chicken RBCs was added to all the
test wells and incubated for 20 minutes. The agglutin-
ation of the RBCs indicated the absence of antibodies
against the AIV H5N1.
Detection of the DNA vaccine distribution in vivo
A PCR analysis was performed on the spleen and mus-
cles to determine the presence of the pDis/H5, pDis/
IL-15 and pDis/IL-18 genomic DNA. The genomic
DNA was extracted from the tissues using 10% sodium
dodecyl sulphate (SDS) and 20 mg/mL of Proteinase K
(Invitrogen, USA). The lysate was extracted by phenol
chloroform isoamyl alcohol (25:24:1) and chloroform
isoamyl alcohol (49:1). The precipitated DNA was used
as PCR templates for detecting the distribution of DNA
vaccines in vivo. A RT-PCR analysis was performed on
the spleen and muscles to determine the presence of
the pDis/H5, pDis/IL-15 and pDis/IL-18 mRNA tran-
scripts based on the methods described in previous
section. The RNA preparations were standardized by
the RT-PCR for β-Actin and were free from DNA con-
tamination evaluated by the lack of amplification fol-
lowing non-reverse transcribed RNA using the same
samples and set of primers (Table 2).
Analysis of CD3 + /CD4+ and CD3+ /CD8+ T-lymphocytes
Chicken peripheral blood samples were collected from
the jugular vein in 2.5 ml syringes containing 0.2 ml of
sodium heparin to prevent clotting. The peripheral
blood mononuclear cells (PBMC) were isolated from the
heparinized chicken’s blood, as described in Ficoll-Paque
PLUS protocol, and a single cell suspension was pre-
pared at a concentration of 1 x 107 cells/mL. Then, 100
μL of cell suspensions (1 × 106 cells) were incubated for
2 hours at 4°C. The chicken lymphocytes were double-
stained with mouse anti-chicken CD3-R-phycoerythrin
(R-PE) (Southern Biotech, USA) and mouse anti-chicken
CD4-FITC (Southern Biotech, USA) or mouse anti-
chicken CD3-R-phycoerythrin (R-PE) (Southern Biotech,Table 2 List of primers used in amplification of mRNA transcr
Primer name Primer sequence
H5f 5’ TGG GAG GAT GGA GTT
H5r 5’ TGG AGT TTG ACA CTT
IL-15f 5’ AAC TTG CTC CAT AGG
IL-15r 5’ AGA GTT TTG TGT TGG
IL-18f 5’ TTC GAA ACG TCA ATA
IL18r 5’ GGG GTC GAC ATT GTC
ß-Actinf 5’ CAT CTA TGA AGG CTA
ß-Actinr 5’ GCT TCT CCT TGA TGT CUSA) and mouse anti-chicken CD8α-FITC (Southern
Biotech, USA). The immuno-stained cells were analyzed
on a FACSCalibur flow cytometer (Becton Dickinson,
San Jose, CA, USA). The small lymphocyte population
was differentiated according to cell size as defined by the
forward scatter (FSC) value and their granularity as
defined by the side scatter (SSC) value using the FSC/
SSC dot plot diagram and subjected to four quadrant
statistics for differentiation of single T cell sub-
populations.Cytokine gene expression analysis
The expression of selected cytokines from frozen spleen
samples was performed using the GenomeLab GeXP
(Beckman Coulter, USA). In brief, the RNA was
extracted using Trizol reagent according to the manu-
facturer's instructions (Invitrogen, USA). A total of 13
cytokine genes, an internal control and a housekeeping
gene (COL6A2) were designed using the GenomeLab
eXpress Profiler software (Table 3). The reverse tran-
scription reactions and PCR amplification were per-
formed according to the GenomeLab GeXP Start Kit
using the Beckman–Coulter protocol. The PCR product
sizes were determined using the GenomeLab GeXP soft-
ware and were compared to the expected PCR product
size to identify each transcript. The data was imported
into the analysis module of the eXpress Profiler soft-
ware. Relative gene expressions of the individual genes
were normalized by dividing the peak area of each gene
by the peak area of the COL6A2 gene following the
method described by Sadava et al. [16].Statistical analysis
An ANOVA was performed using the SPSS Windows
program version 12.0 to analyse the differences between
animal immunization groups under each of the above
three indices (the percentage of CD3+ /CD4+ and
CD3+ /CD8+ subgroups of peripheral blood T-lympho-
cytes, the antibody responses and the GeXP multiplex
gene expression were compared with those of theipt of AIV and chicken cytokine genes
Gene size (bp)
CTT CTG GAC 3’ H5 gene/175
GGT GTT GCA 3’
TTT CCG A 3’ IL-15 gene/126
CTG TGC CAT 3’
GCC AGT TGC 3’ IL-18 gene/161
ATA TTC CTC TGC 3’
CGC CCT 3’ ACTB gene/155
AC GCA CAA 3’
Table 3 Gene name, product size, and forward and reverse primer sequences of GeXP assays of chicken spleen
Gene name Fragment size Left sequence without universals c Right sequence without universalsd
IL-15 187 AAGGTTTCCGAGGCTTGTACC GTTTTCTGACTCTCCGGCCT
IL-12β 194 TGAAGGAGTTCCCAGATGCT AAGAACGTCTTGCTTGGCTC
IL-2 201 TAGTCACGAGGGGACCTTTG GACGGCTTTCTTTGATGAGC
IL-1β 208 TCTTTGGCTGTATTTCGGTAGC TGCACTCCTGGGTCTCAGTT
IL-18 215 CAAAGTGTACACCATCCTGGAA AAAGACGATTCCGCTTTCTTC
IL-4 222 CAAGTCAAAGCCGCACATC GAGGATCCACCAGCTTCTGT
IL-6 236 TCAACATCGCCACCTACAAG TAAAAGCAACGGGACGGTAA
IL-10 243 GCTTGTGGTTCGTCCAGATT GAACAACCATTTTCCCATGC
IL-8 250 GAGCATCCGGATAGTGAATGA TTGAGGGAGGTGCTGCTG
IFN-γ 257 CAACGCAGAAGAAACAGTGC CCCCATTGCAAATGTTGTATC
TNFSF13B 264 AGCCACAGCATCTTCTTCGT TCGAAGGAGAGCCACTCATC
TGFβ 271 CAACCCCCAATGTCTCTGTT ACCAGGAAACAAGCTTGACG
GMCSF 279 CCGTTTCAGGAACCAGAGAG GTCTGGCTGCTGGACATTTT
COL6A2a 287 ATTTTCAATCCAGGGACGAT CTCCTCTTCTCGCAGGTGAA
KANb 325 ATCATCAGCATTGCATTCGATTCCTGTTTG ATTCCGACTCGTCCAACATC
a Gene used for normalization.
b Internal control.
c Forward universal primer sequence (AGGTGACACTATAGAATA).
d Reverse universal primer sequence (GTACGACTCACTATAGGGA).
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ered as significant.
Results
Construction of DNA vaccines
The H5, IL-15 and IL-18 genes were amplified by PCR
and cloned into purified digested pDisplay vectors with
designations of pDis/H5, pDis/IL-15 and pDis/IL-18, re-
spectively. The resulting H5, IL-15 and IL-18 PCR pro-
ducts appeared in agarose gel as DNA bands at expected
sizes of 1722 bp, 564 bp and 486 bp, respectively
(Figure 1).
Expression of the recombinant plasmids in Vero cells
The Western blot analysis, using rabbit anti-H5 poly-
clonal antibody, was reacted with the recombinant
proteins at 2 weeks post-transfection. Two different con-
structs of the H5 gene were analyzed for their ability to
express protein in Vero cells. The recombinant H5 pro-
tein appeared as a band with a molecular weight of
approximately 82 kDa (lane 4, Figure 2b). The observa-
tion of multiple bands in pDis/H5 (66 kDa) might be
due to nonspecific binding by the polyclonal antibody
used in the studies. However, an analysis of another con-
struct showed no expression of the H5 protein (lane 3,
Figure 2b). This might be due to the inability of the con-
struct to express the H5 protein. An indirect immuno-
fluorescence antibody test (IFAT) was performed to
further confirm the expression of the recombinantprotein. As shown in Figure 3, the cells transfected with
pDis/H5 exhibited a bright green fluorescence showing
that individual constructs encoding the H5 protein can
be expressed in the eukaryotic system. No fluorescent
staining was detected from cells that were transfected
with the pDisplay vector only.
Detection of mRNA transcript in Vero cells
The RT-PCR was performed to confirm the presence of
the H5, IL-15 and IL-18 mRNA transcripts in Vero cells.
The RT-PCR analysis revealed that the recombinant
plasmids were transcriptionally active in Vero cells based
on the detection of transcripts of the expected size as in
Figure 4 and Figure 5. In order to ensure that the detec-
tion of the band was associated with the H5, IL-15 and
IL-18 transcripts and was not an amplification from the
plasmid DNA, the extracted RNA samples were pro-
cessed for PCR amplification without the reverse tran-
scription part. No specific band was detected from the
samples indicating that the amplification result was not
from the plasmid DNA.
HI Assay in SPF chickens inoculated with DNA vaccines
Injections of various DNA vaccine formulations yielded
variable HI responses in Trial 1 (Table 4) and Trial 2
(Table 5). Serum samples were collected and the HI titer
was not detected in all the chickens prior to the inocula-
tion of the plasmid DNA. The HI titer was not detected
in the control chickens inoculated with the expression
Figure 1 PCR amplification of (a) H5 gene from pCR2.1 vector and (b) IL-15 and IL-18 genes from pgm2n.pk009.p17 and pgm2n.
pk010.c11, respectively. The DNA band was observed in (a) 1% (w/v) agarose gel. M: 1 kb DNA ladder (Promega, Madison WI); Lane 1: H5 gene
(1722 bp) and (b) 2% (w/v) agarose gel. M: 100 bp DNA ladder (Promega, Madison, WI). Lane 1: IL-15 gene (564 bp); Lane 2: IL-18 gene (486 bp).
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trol. Chickens inoculated with the pDis/H5, pDis/H5 +
pDis/IL-15 and pDis/H5 +pDis/IL-18 groups were able
to develop the HI antibody titer in both trials
respectively.
In Trial 1, three weeks after the booster inoculation,
significant HI Geometric mean titer (GMT) was
detected for the pDis/H5+ pDis/IL-15 group which
increased to 13.00 ± 1.40 HI GMT (p < 0.05). In Trial 2,
one week after the booster inoculation, significant HI
titers were detected for the pDis/H5+ pDis/IL-15 group
which increased to 16.00 ± 0.00 HI GMT (p < 0.05). The
results indicated that the booster inoculation increased
the sero conversion rate of the SPF chickens. Besides
that, the results also indicated that the SPF chickens in
Trial 2 exhibited a shorter time to achieve the highest
HI titer which was 1 week after the booster inoculation
compared to 3 weeks after the booster inoculation in
Trial 1 for pDis/H5+ pDis/IL-15.
There was a significant increase of the HI titer
induced by the pDis/H5+ pDis/IL-18 inoculation at
1 week to 3 weeks after the booster inoculation com-
pared with the pDis/H5 group in Trial 1 (P < 0.05)
(Table 4). However, the pDis/H5 + pDis/IL-18 group
reached a plateau at 6.50 ± 1.40 HI GMT from 3 weeks
to 5 weeks after the booster inoculation. The HI titer in
other time points induced by chicken IL-18 was not
statistically significant (P > 0.05) (Table 4). In Trial 2,
the HI titers induced by the pDis/H5 + pDis/IL-18 at all
the inoculation time points were not significantcompared with the pDis/H5 group (P > 0.05) except at
4 weeks post inoculation (Table 5). In summary, the
data showed that the pDis/IL-15 plasmid DNA was able
to enhance the antibody production together with the
pDis/H5 construct through the i.m. route of
inoculation.CD3+/CD4+ and CD3+/CD8+ T cells population following
pDis/H5, pDis/H5 + pDis/IL-15 and pDis/H5 + pDis/IL-18
inoculation
Prior to the inoculation of the plasmid DNA, the per-
centage of CD3+/CD4+ and CD3+/CD8+ T cells popula-
tion were 2.92 ± 0.40 and 0.52 ± 0.24 in Trial 1
respectively. Meanwhile, the percentage of CD3+/CD4+
and CD3+/CD8+ T cells population were 2.64 ± 0.40
and 0.69 ± 0.24 in Trial 2 respectively. The level of the
CD3+/CD4+ T cells population in the pDis/H5, pDis/
H5 + pDis/IL-15 and pDis/H5 + pDis/IL-18 groups in
Trial 1 (Table 6) and Trial 2 (Table 7) were significantly
higher compared to the control group (P < 0.05). The
pDis/H5+ pDis/IL-15 inoculated group showed the
highest CD3+/CD4+ T cells population at 2 weeks and
5 weeks post inoculation in Trial 1 and at 3 weeks
and 6 weeks post inoculation in Trial 2 respectively,
compared to the other inoculated groups (P < 0.05).
The pDis/H5+ pDis/IL-18 inoculated group in Trial 2
showed a significant CD3+/CD4+ T cells level compared
to the pDis/H5 group at 3 weeks and 6 weeks post
inoculation (P< 0.05). However, the pDis/H5+pDis/IL-18
Figure 2 SDS-PAGE and Western blot analysis of Vero cells transfected with recombinant plasmid, pDis/H5. (a) Cell lysates were
separated on 12% SDS-PAGE (b) Western blot with transferred protein samples incubated with primary antibodies against H5 of AIV and
anti-rabbit secondary antibodies conjugated with alkaline phosphatase. M: BenchMarkTMPre-Stained Protein Ladder. Lane 1: Non-transfected Vero
cell lysates; Lane 2: pDisplay vector; Lane 3: pDis/H5 vector 1; and 4: pDis/H5 vector 2. Distinct band of 82 kD which corresponds to the H5
protein of AIV was detected in lane 4 (arrowhead) whilst, pDis/H5 vector 1 construct failed to show H5 expression.
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induce the CD3+/CD4+ T cells at 2 weeks and 5 weeks
post inoculation compared to the pDis/H5 (P > 0.05).
The level of the CD3+/CD8+ T cells population in the
pDis/H5, pDis/H5 + pDis/IL-15 and pDis/H5+ pDis/IL-
18 groups in Trial 1 at 2 weeks post inoculation were
significantly higher compared to the control as shown in
Table 8 (P < 0.05). However, only the pDis/H5 inoculated
group in Trial 1 at 5 weeks post inoculation showed sig-
nificant CD3+/CD8+ T cells level compared to the con-
trol group (P < 0.05). Similarly, only the pDis/H5
inoculated group in Trial 2 at 6 weeks post inoculation
showed significant CD3+/CD8+ T cells level compared
to the control group (P < 0.05). Overall, the pDis/H5 +
pDis/IL-15 does not influence the CD3+/CD8+ T cellslevel in the PBMC except at 2 weeks post inoculation in
Trial 1 (P < 0.05).
Detection of transgene in vaccinated SPF chickens
The stability of the plasmid construct and the duration
of the transgene expression in the immunized SPF chick-
ens were determined by extracting the total genomic
DNA and total RNA from chicken breast muscle and
spleen for the PCR and RT-PCR analyses. The H5, IL-15
and IL-18 genes could be amplified by PCR and RT-PCR
in groups immunized with the DNA vaccine, while
chickens vaccinated with the empty plasmid, pDisplay,
showed negative results. The PCR analysis on the
extracted genomic DNA showed that the plasmid con-
structs were stable in the injected muscle as long as
Figure 3 Stable expression of Vero cells with (a) pDisplay vector, (b) pDis/H5. Recombinant H5 proteins expression was detected by IFAT
assay and visualized in bright field (BF) and fluorescence (F). Vero cells transfected with pDisplay vector as negative control.
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http://www.biomedcentral.com/1746-6148/8/1326 weeks after vaccination. The transgene expression was
reached systematically in the spleen and not only in the
muscle at the injection site in both trials (Figure 6).GeXP analysis of gene expression in chicken spleens
A GeXP assay was performed to detect the expressions
of 13 chicken cytokines including Th1, Th2 and pro-
inflammatory cytokine genes (Table 3) in the spleen at
the end of the experiment (56-day-old) after two DNA
inoculations. A housekeeping gene, COL6A, was used to
normalise the expression of the genes. The GeXP analysis
showed that the expressions of TGF-β, GMCSF, IL-4,
TNFSF13B, IL-1β, IL-15, IL-18, IFN-γ, IL-12β were
detected in both trials. Except for IL-15 and IL-18, those
genes showed a low level of gene expression ranging
from 0.01 to 0.17 following the H5 DNA vaccination
(data not shown). As shown in Table 8, the expressions
of IL-15 and IL-18 in the control un-inoculated chickens
were between 0.10 to 0.62. The level of the IL-15 gene
expression in the pDis/H5, pDis/H5 + pDis/IL-15 and
pDis/H5+ pDis/IL-18 groups in both trials (Table 8) weresignificantly higher compared to the control group
(P < 0.05), except for the pDis/H5+ pDis/IL-18, which
was not significant compared to the control group
(P > 0.05) in the first trial. In addition, the pDis/H5 +
pDis/IL-15 inoculated group showed the highest IL-15
gene expression in both trials compared to the other
inoculated groups (P < 0.05). This showed that the co-
administration of SPF chickens with pDis/IL-15 was able
to induce a higher IL-15 gene expression than the pDis/
H5 group (P < 0.05). Similar results were obtained for the
IL-18 expression, where the pDis/H5 + pDis/IL-18 groups
in both trials (Table 8) were significantly higher com-
pared to the control group (P < 0.05). Meanwhile, pDis/
H5, pDis/H5+ pDis/IL-15 did not induce a significant
level of IL-18 compared to the control group (P > 0.05).Discussion
The in vivo studies using SPF chickens were conducted
after confirming that all the plasmid constructs were
able to express the desired proteins and were transcrip-
tionally active in the in vitro expression analysis. In
Figure 4 RT-PCR analysis of total RNA extracted from transfected Vero cells. RT-PCR analysis of the transfected Vero cells showed the
presence of H5 transcript in the transfected cell lysate. The products were resolved in 2% (w/v) agarose gel in TAE. M: 100 bp DNA ladder
(Promega, Madison WI); Lane 1 and 2: H5 transcript (175 bp) (b) No specific band was observed when RNAs was analyzed by PCR without the RT
part as in Lane 3 and 4: H5.
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http://www.biomedcentral.com/1746-6148/8/132addition, the transgenes were stable over a period of
6 weeks after the booster dose, thus implying the poten-
tial that the plasmid DNAs encoding the target proteins
could be expressed over a sustainable period.
Chickens inoculated with pDis/H5+ pDis/IL-15 at
4 weeks post inoculation in Trial 1 (Table 4) and Trial 2Figure 5 RT-PCR analysis of total RNA extracted from transfected Ver
presence of IL-15 and IL-18 transcripts in the transfected cell lysate. The pro
ladder (Promega, Madison WI); (a) Lane 1 to 3: IL-15 transcript (126 bp), Lan
when RNAs were analyzed by PCR without the RT part as in Lane 7 to 9: IL(Table 5) showed a 2.82 fold and 4.87 fold increase in
the HI antibody titer respectively, compared to pDis/H5
expressing the H5 alone (P < 0.05), suggesting that IL-15
plays a role in enhancing the humoral immune response.
This finding was comparable with several studies con-
ducted in different animal models where the recombinanto cells. RT-PCR analysis of the transfected Vero cells showed the
ducts were resolved in 2% (w/v) agarose gel in TAE. M: 100 bp DNA
e 4 to 6: IL-18 transcript (161 bp). (b) No specific band was observed
-15 and Lane 10 to 12: IL-18.





1 2* 3 4 5 6 7
Control 0 0 0 0 0 0 0
pDisplay 0 0 0 0 0 0 0
pDis/H5 1.52 ±1.38 1.62 ±1.43 1.87 ±1.43 2.30 ±1.34 3.25 ±1.60 4.92 ±1.60 6.50 ±1.40
pDis/H5+ pDis/IL-15 1.52 ±1.43 1.62 ±1.60 5.28 ±1.43a c 6.50 ±1.40a 13.00 ±1.40a c 10.56 ±1.43a c 12.13 ±1.43a c
pDis/H5+ pDis/IL-18 1.52 ±1.43 2.30 ±1.55 3.25 ±1.40b 4.92 ±1.40b 6.50 ±1.40b 6.50 ±1.40 6.50 ±1.40
* Chickens were given a booster 2 weeks after initial inoculation. Statistically significant differences (P < 0.05) are indicated by a, pDis/H5 compared with
pDis/H5 + pDis/IL-15; b, pDis/H5 compared with pDis/H5 + pDis/IL-18; c, pDis/H5 + pDis/IL-15 compared with pDis/H5 + pDis/IL-18.
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http://www.biomedcentral.com/1746-6148/8/132vaccinia virus vaccine with integrated IL-15 expressing
gp160 of human immunodeficiency virus generated a
more robust and durable antibody response compared to
gp160 alone [17]. In another study, the recombinant vac-
cinia virus-based pentavalent H5N1 AI vaccine adju-
vanted with the human IL-15 induced stronger
neutralizing antibodies against the AIV H5 in mice [18].
Another study demonstrated that the recombinant pro-
tein from the Eimeria acervulina in combination with the
chicken IL-15 against coccidiosis which exhibited signifi-
cantly greater serum IgG antibody levels than with the re-
combinant protein alone in ovo [19].
This study also showed an increased in the HI titer by
the pDis/H5+ pDis/IL-18 at 4 weeks post inoculation in
Trial 1 (Table 4) and Trial 2 (Table 5) by 2.14 fold and
2.00 fold respectively, compared to the pDis/H5 expres-
sing the H5 alone (P < 0.05). Several reports have shown
that the plasmid encoding IL-18, which is used as an ad-
juvant in mammalian vaccines, promote high antibody
titers [20,21]. The recombinant chicken IL-18 has been
shown to significantly enhance antibody responses to
the Clostridium perfringens α-toxoid and NDV antigens
[22]. Higher HI titers induced in chickens immunized
with the Newcastle disease vaccine co-administratedTable 5 HI titer of serum samples obtained from chickens






Control 0 0 0
pDisplay 0 0 0
pDis/H5 2.69 ± 1.45 3.28 ± 1.40 3.28 ± 1.40
pDis/H5+ pDis/IL-15 3.62 ± 1.30c 16.00 ± 0.00a c 11.89 ± 1.45a c
pDis/H5+ pDis/IL-18 2.21 ± 1.30 6.56 ± 1.95b 4.42 ± 1.87
* Chickens were given a booster 3 weeks after initial inoculation. Statistically
significant differences (P < 0.05) are indicated by a, pDis/H5 compared with
pDis/H5 + pDis/IL-15; b, pDis/H5 compared with pDis/H5 + pDis/IL-18; c, pDis/
H5 + pDis/IL-15 compared with pDis/H5 + pDis/IL-18.with chicken IL-18 further confirm the immunostimula-
tory activities of chicken IL-18 in vivo [23].
The highest HI GMT of 16 ± 0.00 was observed in SPF
chickens at 4 weeks post inoculation after two pDis/
H5 + pDis/IL-15 inoculations were given in Trial 2. This
is comparable to the studies conducted by our group
where chickens immunized intramuscularly with the H5
DNA vaccine with genetic adjuvants, such as MDP-1,
Esat-6 and HSP70 of the Mycobacterium tuberculosis,
developed a higher HI titer compared to the H5 DNA
vaccine alone [24-26]. However, all the previous studies
required three vaccinations to achieve a comparable HI
titer. Generally, the HI titer obtained in the present
study was low compared to the following studies using
inactivated AI vaccine. Chickens vaccinated with inacti-
vated AI vaccine with HI GMT of 10 to 40 were asso-
ciated with the prevention of mortality and HI GMT of
80 or more were associated with protection for mortality
[27]. However, a previous study has shown that although
the HA gene DNA vaccine induced a low HI antibody
level after two DNA injections, immunized chickens
were still protected against the lethal HPAI virus chal-
lenge [28], suggesting the role of other immune compo-
nents, particularly in cellular immunity. Previous studies
have shown that although the antibody against HA
played a role in neutralizing viral infectivity, cellular im-
munity plays an important role in viral clearance [29,30].
The flow cytometry results for both trials (Table 6 and
Table 7) demonstrated that pDis/H5, pDis/H5+ pDis
/IL-15 and pDis/H5 + pDis/IL-18 were able to trigger
higher CD4+ T cell production upon inoculation. The
co-administration of SPF chickens with the pDis/IL-15
adjuvant was able to induce a higher production of CD4
+ T cells than the pDis/H5 group (P < 0.05). These find-
ings were consistent with previous reports that IL-15
has profound effects on the proliferation and survival of
CD4+ T cells [31]. On the other hand, the present study
revealed that pDis/IL-15 was not significant (P > 0.05) in
inducing CD8+ T cells (Table 6). Nevertheless, in mam-
malian studies, IL-15 has been shown to support the
Table 6 Immunophenotyping of CD3+/CD4+ and CD3+/CD8+ lymphocytes from chickens following inoculation with






Week 2 Week 5 Week 2 Week 5
Control 2.23 ± 0.60 1.55 ± 0.26 0.91 ± 0.30 1.79 ± 0.58
pDisplay 2.55 ± 0.36 1.76 ± 0.14 1.16 ± 0.46 2.00 ± 0.35
pDis/H5 4.53 ± 0.33 * 4.19 ± 0.52* b 3.16 ± 0.56* a b 2.97 ± 0.55* a b
pDis/H5+ pDis/IL-15 6.98 ± 0.73* a c 6.28 ± 0.60* a c 1.94 ± 0.46* 1.64 ± 0.44
pDis/H5+ pDis/IL-18 4.46 ± 0.34* 3.45 ± 0.26* 2.31 ± 0.84* 1.95 ± 0.52
Each value represents the mean percentages of T cell sub-populations ± SD. The percentage of CD3+/CD4+ and CD3+/CD8+ T cells before inoculation are
recorded as 2.92 ± 0.40 and 0.52 ± 0.24, respectively. Statistically significant differences (P < 0.05) are indicated by an asterisk (*), treated compared with
untreated groups; a, pDis/H5 compared with pDis/H5 + pDis/IL-15; b, pDis/H5 compared with pDis/H5 + pDis/IL-18; c, pDis/H5 + pDis/IL-15 compared with
pDis/H5 + pDis/IL-18.
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and Table 8, the presence of the IL-15 transcript in the
spleen and muscles of chickens indicated that chicken
IL-15 was able to express in vivo and the low level of
CD8+ T cells was not due to the absence or low expres-
sion of the IL-15 protein.
The flow cytometry results in Trial 2 (Table 7) demon-
strated that the co-administration of pDis/H5 + pDis/
IL-18 was able to trigger a higher CD4+ T cell prolifera-
tion than the pDis/H5 group (P < 0.05). These findings
were consistent with previous reports that IL-18 yielded
stronger CD4+ T cell responses in immunized mice [13]
and chickens [34] thus enabling DNA vaccines to
achieve enhanced immune responses. On the other
hand, the reports also showed that the co-administration
of the IL-18 plasmid as an encoded adjuvant yielded
stronger CD8+ T cells [35]. However, both trials in the
present study revealed that pDis/IL-18 was not signifi-
cant (P > 0.05) in inducing CD8+ T cells in the inocula-
tion group. This indicated that IL-18 did not influence
CD8+ T cell proliferation significantly, at least not in the
PBMC samples at 2 weeks and 5 weeks post inoculationTable 7 Immunophenotyping of CD3+/CD4+ and CD3+/CD8+







Control 2.96 ± 0.52 7.
pDisplay 2.83 ± 0.34 7.
pDis/H5 6.56 ± 0.26* 8.
pDis/H5+ pDis/IL-15 10.65 ± 0.59* a c 13.
pDis/H5+ pDis/IL-18 8.42 ± 1.08* b 11.
Each value represents the mean percentages of T cell sub-populations ± SD. The p
recorded as 2.64 ± 0.40 and 0.69 ± 0.24, respectively. Statistically significant differen
untreated groups; a, pDis/H5 compared with pDis/H5 + pDis/IL-15; b, pDis/H5 comp
pDis/H5 + pDis/IL-18.in Trial 1 and 3 weeks and 6 weeks post inoculation in
Trial 2.
This study also suggests that the age of the SPF chick-
ens at the time of inoculation could have influenced the
immune response of the chickens, where chickens
inoculated when they were 14 days old showed a higher
HI antibody titer compared to those vaccinated when
they were a day old (Table 4 and 5). This finding is com-
parable to studies which have shown that the priming of
the SPF chickens at different ages played a significant
role in determining the immune responses [36,37]. The
results in this study showed that the transgenes were
stable over a period of 6 weeks after the booster dose,
thereby implying the potential that the plasmid DNAs
encoding the target proteins could be expressed over a
sustainable period. A previous study has shown that
chickens vaccinated with the DNA vaccine resulted in
the distribution of the target genes in the heart, lungs,
liver, spleen and kidneys [38].
The cytokine expression levels of the immunized
chickens were evaluated using GeXP analysis. The GeXP
assay was designed originally for a high throughput andlymphocytes from chickens following inoculation with
CD3+/CD8+
ek 6 Week 3 Week 6
25 ± 0.71 1.50 ± 0.28 3.58 ± 1.15
42 ± 0.47 1.51 ± 0.66 3.28 ± 0.71
86 ± 0.17* 2.52 ± 1.00 5.49 ± 1.15* a
59 ± 1.15* a c 2.26 ± 0.38 3.53 ± 0.59
61± 0.61* b 2.12 ± 0.81 4.22 ± 1.21
ercentage of CD3+/CD4+ and CD3+/CD8+ T cells before inoculation are
ces (P < 0.05) are indicated by an asterisk (*), treated compared with
ared with pDis/H5 + pDis/IL-18; c, pDis/H5 + pDis/IL-15 compared with




Trial 1 Trial 2
IL-15 IL-18 IL-15 IL-18
Control 0.62 ± 0.10 0.13 ± 0.03 0.41 ± 0.07 0.10 ± 0.02
pDisplay 0.41 ± 0.05 0.11 ± 0.03 0.51 ± 0.02 0.15 ± 0.00
pDis/H5 1.38 ± 0.11* b 0.14 ± 0.06 1.20 ± 0.13* b 0.17 ± 0.03
pDis/H5+ pDis/IL-15 3.69 ± 0.51* a c 0.19 ± 0.05 3.53 ± 0.33* a 0.18 ± 0.04
pDis/H5+ pDis/IL-18 0.74 ± 0.06 0.45 ± 0.02* b c 0.95 ± 0.12* 0.69 ± 0.13* b c
Note: Each value represents the mean ± SD. Statistically significant differences (P < 0.05) are indicated by an asterisk (*), treated compared with untreated groups;
a, pDis/H5 compared with pDis/H5 + pDis/IL-15; b, pDis/H5 compared with pDis/H5 + pDis/IL-18; c, pDis/H5 + pDis/IL-15 compared with pDis/H5 + pDis/IL-18.
Figure 6 RT-PCR analysis of mRNA extracted from spleen and muscles from chickens vaccinated with pDis/H5, pDis/H5+pDis/IL-15
and pDis/H5+pDis/IL-18. The products were resolved in 1% (w/v) agarose gel in TAE. M: 100 bp DNA ladder (Promega, Madison WI) or VC
100 bp Plus DNA ladder (Vivantis, Malaysia) Lane 1: ACTB; Lane 2: H5 transcript in left muscle tissues; Lane 3: H5 transcript in right muscle tissues;
Lane 4: H5 transcript in spleen. Lane 5: IL-15 or IL-18 transcript in left muscle tissues; Lane 6: IL-15 or IL-18 transcript in right muscle tissues; Lane
7: IL-15 or IL-18 transcript in spleen. In (A): RT-PCR analysis of mRNA. In (B): No specific band was detected when RNA from (A) was analyzed by
PCR without the RT part.
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profile by a single RT-PCR [39]. The assay has a high
dynamic linear range and improved sensitivity and
specificity compared to other platforms [40]. The co-
administration of the H5 DNA vaccinated SPF chickens
with the pDis/IL-15 adjuvant was able to induce higher
IL-15 gene levels than the control group (P < 0.05). How-
ever, only low levels of the IL-18 gene were observed
among the treatment groups compared to the control
group. Other cytokine genes including the TGF-β,
GMCSF, IL-4, TNFSF13B, IL-1β, IFN-γ, IL-12β showed
low levels of gene expression following the H5 DNA vac-
cination, probably due to the fact that the 56-day-old
chicken spleens were collected at the end of the
experiment.
In this study, we evaluated the immuno-regulatory
effects of the co-administration of pDis/H5+ pDis/IL-15
or pDis/IL-18 via assessed on the peripheral blood CD4
and CD8 population and the cytokine expression levels.
These results provide evidence that the pDis/IL-15 adju-
vant was able to increase the CD4+ T cell population
and stimulate the expression of IL-15 which might play
a part in immunity against influenza via the induction
and maintenance of CD8+ T cell memory, and providing
help to B cells for antibody production. However, studies
on the biological activities of IL-15 and IL-18 using the
in vitro recall assay or evaluation on the regulation of
cytokines on the NK cell (CD3-/CD8+) activity and
interferon-γ production should be further appraised in
the future together with the challenge of the H5N1 virus
against the vaccinated chickens. These studies can con-
tribute to the understanding on the role of the pDis/IL-
15 adjuvant as a protection against the AIV.
Conclusions
In conclusion, the results in this study demonstrate that
pDis/H5+ pDis/IL-15 has the potential to be used as a
DNA vaccine against AIV in chickens. Further studies
are currently underway in exploring the possibility of
conferring chickens immunized with pDis/H5 + pDis/
IL-15 with protection against the challenge of the H5N1.
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